Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
NCT00423865
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also help cisplatin work better by making tumor cells more sensitive to the drug. Giving cisplatin together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side eff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)
NCT01487499
Terminated
This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions: 1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls 2. to implement a pro... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/15/2015
Locations: University of Florida, Gainesville, Florida
Conditions: Small Cell Lung Cancer
Register for Updates
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
NCT01222572
Terminated
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2015
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Register for Updates
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
NCT00930930
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving chemotherapy together with everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not ye... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2015
Locations: University of Alabama, Birmingham, Alabama +7 locations
Conditions: Breast Cancer
Register for Updates
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011
Completed
Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. It is not yet known which combination chem... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/30/2015
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer
Register for Updates
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
NCT00885534
Completed
The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide. We and other investigators have used CVT in melanoma patients and found that tumors got significantly smaller in 30-40% of cases. In this study, the investigators want to get a precise idea of how many patients will respond to CVT. Also they want to test which genes in the tumor are turned on and which are turned off. We hope th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2015
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Melanoma, Skin Cancer
Register for Updates
Effects of Exercise in Combination With Epoetin Alfa
NCT00577096
Completed
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (PBSC T) for multiple myeloma. The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2015
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
NCT01953952
Withdrawn
This randomized phase II trial studies radiation therapy and cisplatin with or without surgery in treating patients with stage III-IV oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with radiation therapy may kill more tumor cells. It is not yet known whether radiation thera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2015
Locations: Stanford University Hospitals and Clinics, Stanford, California
Conditions: Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Tongue Cancer
Register for Updates
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
NCT00254904
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of gemcitabine/cisplatin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Birmingham, Alabama +120 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
NCT00005834
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +92 locations
Conditions: Multiple Myeloma
Register for Updates
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00006237
Completed
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa is more effective with or without combination chemotherapy and interleukin-2 for melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +296 locations
Conditions: Melanoma (Skin)
Register for Updates
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
NCT00723658
Withdrawn
RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut +28 locations
Conditions: Lymphoma
Register for Updates